Orthostatic hypotension is defined as the reduction of systolic blood pressure of at least 20 mmHg or the dropping of diastolic blood pressure of at least 10 mmHg within 3 minutes of standing compared to baseline values [1]. Recent studies suggest a change in reference values to 30 mmHg in diabetic patients and hypertensive subjects with clinicostatic systolic blood pressure higher than 160 mmHg [1,2], as this would more accurately estimate the probability of autonomic neuropathy in those populations. Multiple system atrophy is a neurodegenerative disorder characterised by parkinsonian features, cerebellar ataxia, and autonomic failure. In a recent consensus, reference values for the diagnosis of orthostatic hypotension in multiple system atrophy have been upgraded to 30 mmHg in systolic blood pressure or 15 mmHg in diastolic blood pressure, within 3 minutes of standing [3].

Orthostatic hypotension can be divided into neurogenic and non neurogenic forms. Neurogenic forms are caused by a primitive damage to autonomic nervous system. Non neurogenic forms involve organs or systems regulating metabolic homeostasis and hemodynamics of the organism; in other instances, they may also be determined by external factors, such as the use of drugs, alcohol and other substances [4].

Drugs are the most common cause of non neurogenic orthostatic hypotension; they may also complicate or aggravate neurogenic forms.

Orthostatic hypotension is a common cause of falls and syncope, especially in elderly people [5-7]. Longitudinal studies have demonstrated an association between orthostatic hypotension and increased cardiovascular morbidities (such as coronary artery disease [8,9] and stroke [10]), and between orthostatic hypotension and mortality in the general population [8,11].

Moreover, when orthostatic hypotension is due to an adverse drug reaction, it is common in clinical practise to observe a general loss of compliance to therapies. To optimize a treatment with vasoactive drugs, by avoiding orthostatic hypotension, represents a matter of enormous importance in the management of lifelong-treated patients with neurological and cardiovascular diseases.

**Antiparkinsonian Drugs**

Orthostatic hypotension plays an important role in Parkinson’s disease (PD): its prevalence ranges between 14% and 80% [12]. It is related to older age, severity and duration of the disease [13,14] and can be caused by autonomic dysfunction, drugs, or both causes. Few studies have evaluated the specific mechanisms of orthostatic hypotension in patients with PD. Lowering of blood pressure may be mainly due to drugs (in particular levodopa), when autonomic cardiovascular function tests are normal [15]. On the other hand, the absence of activation of compensatory chronotropic mechanisms to low blood pressure while standing may be due to autonomic failure [16].

Dopaminergic agonists (levodopa, carbidopa) frequently cause orthostatic hypotension, even at the beginning of therapy, through the activation of dopamine receptors, determining cutaneous, mesenteric and renal vasodilatation, but also through other mechanisms, such as a reduced central sympathetic tone, which causes a small reduction in heart rate, and an impaired release of renin and aldosterone [17,18]. However, among antiparkinsonian drugs, selegiline seems to be more frequently involved in the onset of orthostatic hypotension, even after long-term therapy, if compared to levodopa [16,19]. Furthermore, while combined treatment with both drugs can determine severe orthostatic hypotension [20,21], levodopa alone is less often responsible for this phenomenon. In fact, in addition to the peripheral vasodilatation due to dopamine agonists, the decreased reuptake of dopamine and norepinephrine in central nervous system caused by selegiline causes a reduction in sympathetic tone [22]. Ha et al. [13] did not find a significant difference in dopaminergic agonist doses between PD patients with and without symptoms related to orthostatic hypotension, suggesting that other factors, such as age and other concomitant therapies, may be responsible for orthostatic hypotension in PD [13]. These data were further confirmed by Perez-Lloret et al.

**Keywords:** Orthostatic hypotension; Adverse drug reaction; Hypertension; Anti-hypertensive treatment; Parkinson’s disease

**Abstract**

Orthostatic hypotension is defined as the reduction of systolic blood pressure and non neurogenic forms. Neurogenic forms are caused by a primitive damage to autonomic nervous system, while drugs are the most common cause of non neurogenic orthostatic hypotension; they may also complicate or aggravate neurogenic forms.

Many drugs can determine orthostatic hypotension, including both cardiovascular drugs and therapies used for neurological and psychiatric disorders. This effect is furthermore enhanced by multiple pharmacological treatments. It is important for the clinician to know the potential hazard of orthostatic hypotension, in order to avoid syncope, falls, hypoperfusion symptoms, excess of mortality and loss of compliance to treatment.

**References**

1. Valeria Milazzo, Cristina Di Stefano, Serena Servo, Valentina Crudo, Chiara Fulcheri, Simona Maule and Franco Veglio

1. Autonomic Unit and Hypertension Unit, Department of Medicine and Experimental Oncology, S. Giovanni Battista Hospital, University of Turin, Turin, Italy
2. Department of Neurology, Maggiore Della Carità Hospital, Eastern Piedmont University, Novara, Italy

**Corresponding author:** Dr. Valeria Milazzo, SCDU Medicina 4, Azienda Ospedaliera S. Giovanni Battista, Corso Bramante 88, 10126 Torino, Italy, Tel: 390 116 336 959; Fax: 390 116 336 931; E-mail: Valeria.Milazzo@libero.it

**Received** March 03, 2012; **Accepted** March 23, 2012; **Published** March 26, 2012

**Citation:** Milazzo V, Stefano CD, Servo S, Crudo V, Fulcheri C, et al. (2012) Drugs and Orthostatic Hypotension: Evidence from Literature. J Hypertens 1:104. doi:10.4172/2167-1095.1000104

**Copyright:** © 2012 Milazzo V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
there are no sufficient data to choose a class of anesthetic over the other in patients who are at high risk for intra-operative hypotension. In these patients, especially during a spinal block, concurrent intravenous administration of ketamine is indicated in order to obtain hemodynamic stability, due to its indirect sympathomimetic effect [32-34].

**Antidepressants and Antipsychotics**

Treatment of depression in elderly patients with cardiovascular diseases often determines orthostatic hypotension: this issue has been studied for many years. Craig [35] described 50 cases of orthostatic hypotension in elderly patients: in 40 of them the cause was iatrogenic. Diuretics were identified as the leading cause of orthostatic hypotension in these patients. After these, 26% of cases were due to the assumption of benzodiazepines, 24% to antidepressants (amitryptiline, in particular) and 22% to antiparkinsonian drugs (among 11 patients treated for PD, 6 were taking L-dopa, 2 selegline, 2 anticholinergic drugs and 1 bromocriptine). Antidepressants and antipsychotics may induce orthostatic hypotension through the inhibition of sodium, potassium and calcium channels in the synapses. Recently it has been described that symptomatic orthostatic hypotension may not only be due to “classic” antidepressants (such as tricyclics, monoamine oxidase inhibitors and neuroleptics) but also to selective serotonin reuptake inhibitors and new antipsychotics [36-38]. Mechanisms through which tricyclic antidepressants may induce hypotension are well known: the blockade of postsynaptic α1 receptors and, in the first phase of therapy, also the blockade of pre-synaptic α2 receptors [24,39]. Among the selective serotonin reuptake inhibitors, fluoxetine and citalopram appear to induce orthostatic hypotension through inhibition of calcium channels leading to vasodilatation [36,40]. Fluoxetine also acts on vasomotor centers in the central nervous system, leading to an increased risk of hypotension, orthostatic hypotension and syncope, especially in elderly people [41].

Antipsychotics, including chlorpromazine, clozapine and risperidone, frequently cause orthostatic hypotension, acting on α1 postsynaptic receptors. Atypical neuroleptics seem to be frequently responsible for orthostatic hypotension, but data are limited [24,42]. In a recent study by Shi et al. [43], in which eight subjects underwent measurement of blood pressure in supine and standing position during different drug treatments (without drugs; midodrine only; promethazine only; midodrine and promethazine), orthostatic hypotension had an increased incidence during treatment with promethazine (p < 0.01), even in combination with midodrine (p < 0.05). This effect is probably due to inhibition of responses in the sympathetic and renin-angiotensin systems.

**Opioid Analgesics**

Regarding treatment with opioid analgesics, blood pressure is generally unchanged, except in cases in which the cardiovascular system is under stress. In this instance, hypotension is mediated by peripheral arterial and venous dilatation due to various factors, such as histamine release and depression of vasomotor center. For example, morphine may cause orthostatic hypotension through peripheral vasodilatation, decreased peripheral resistance and reduced vasomotor reflexes [24]. Particular attention should therefore be placed towards patients with hypovolemia, who are more sensitive to lowering of blood pressure.

**Antihypertensive and Cardiovascular Drugs**

Cardiovascular drugs are often related to orthostatic hypotension.

---

[Citation: Milazzo V, Stefano CD, Servo S, Crudo V, Fulcheri C, et al. (2012) Drugs and Orthostatic Hypotension: Evidence from Literature. J Hypertens 1:104. doi: 10.4172/2167-1095.1000104]
Antihypertensive drugs may be classified into seven classes: calcium channel blockers (dihydropyridine and non-dihydropyridine), diuretics, renin-angiotensin-aldosterone system inhibitors (angiotensin convertase enzyme (ACE) inhibitors, angiotensin II receptor blockers, direct renin inhibitors), α-blockers, β-blockers, centrally acting drugs, and direct vasodilators [24].

On average, 11.9 to 73% of patients with orthostatic hypotension are taking medications [44,45]. Besides the type and mechanism of action of each drug, the total number of vasoactive drugs is crucial. In a study by Poon and Braun [46] in elderly subjects, prevalence of orthostatic hypotension was 35% in naive individuals and 65% in those taking at least three vasoactive drugs (p = 0.002). The study of Kamaruzzaman et al. [47], carried out on a cohort of elderly women, confirms this trend. In this study, predictors of orthostatic hypotension are poorly controlled hypertension (prevalence 38% vs. 21% in hypertensive patients well controlled by therapy, p < 0.001), and the use of at least three vasoactive drugs (OR 1.99, 95% CI 1.30 to 3.05, p = 0.003). Another study [48] shows that in elderly hypertensive patients undergoing pharmacological wash-out, prevalence of orthostatic hypotension is reduced from 23% to 0% during 12 months (p < 0.05), while there are no differences in people who did not undergo therapeutic changes.

In literature there are also counter-trend data. In two studies, the first carried out on elderly residents in long-term care [23] and the second focused on comparing hypertensive and normotensive individuals [49], a strong correlation between orthostatic hypotension and supine high blood pressure was detected, while there was no correlation with the antihypertensive treatment (no statistical significance [23]; RR 0.41, 95% CI 0.18 to 0.93, p = 0.034 [49]).

These data suggest that optimal treatment of hypertension may improve blood pressure regulation and may reduce orthostatic intolerance, which is often seen in patients on polytherapy with vasoactive drugs and diuretics. Masuo et al. [50] compared the prevalence of orthostatic hypotension in a population of normotensive and hypertensive elderly people before and after the beginning of an antihypertensive treatment. Orthostatic hypotension was decreased in hypertensive subjects after treatment (prevalence of orthostatic hypotension pre-treatment: 20% in hypertensive subjects, 4% in normotensive, p = 0.159; post-treatment: 1% in hypertensive subjects, 4% in normotensive, p = 0.406). These data suggest that optimal long-term antihypertensive treatment may result in reducing the burden of orthostatic hypotension.

Among antihypertensive therapy, each drug class is related to a different prevalence of orthostatic hypotension, sometimes correlated to the specific mechanisms of action.

Table 1 resumes cardiovascular drugs potentially implicated in hypotensive events and orthostatic hypotension.

### Nitrites

Nitrites may determine orthostatic hypotension through the induction of vasodilatation, predominantly on the venous district, due to the release of nitric oxide. Nitric oxide activates the enzyme guanylate cyclase and determines an increase in cGMP. Although orthostatic hypotension is listed as an adverse drug reaction in the data sheets of these drugs and severe hypotension is reported as a contra-indication, in population studies no data of significant correlation are available [51,52]. This may be due to the absence of a significant number of people treated with these drugs in the analyzed population. Although in combination with other vasoactive drugs nitrites may be significantly associated with orthostatic hypotension or syncopal events related to excessive blood pressure fall in orthostatism (p < 0.001) [5], Kamaruzzaman et al. [47] identify a weak protective effect against orthostatic hypotension using nitrites (RR 0.70, 95% CI 0.51 to 0.96, p = 0.05), probably consequent to the development of tolerance during protracted treatment.

### Calcium Channel Blockers

Calcium channel blockers act on L-type calcium channels, reducing the entrance of calcium into smooth muscle cells of blood vessel walls. In this way, they determine vasodilatation, mainly on arterioles. Luukinen et al. [53] and Vara Gonzalez et al. [54] showed that treatment with calcium channel blockers is an independent risk factor for orthostatic hypotension, especially with non-dihydropyridine calcium channel blockers (RR 3.23, 95% CI 1.05 to 9.87). There are no studies that correlate dihydropyridine calcium channel blockers (in particular amlodipine [55] and nicardipine [56,57]) to orthostatic hypotension. This is likely due to their major effect towards vascular smooth muscle cells: during treatment with this class, compensatory increase in heart rate as a result of adrenergic stimulation on sinoatrial node is still possible. On the other hand, the prevalent effect of non-dihydropyridine calcium channel blockers is dromotropic negative and inotropic negative. These drugs may determine, in fact, orthostatic hypotension is because of the lack of compensatory chronotropic response on standing [54]. In main population studies which analyzed the overall class of calcium channel blockers (without distinctions between dihydropyridines and non-dihydropyridines), orthostatic hypotension shows a 2-to-5-times increase in prevalence during treatment with these drugs, especially in elderly population [8,53,58], while there is no association between the use of calcium channel blockers and orthostatic hypotension in diabetes [52,59].

### ACE Inhibitors and Angiotensin II Receptor Antagonists

The drugs acting directly on the renin-angiotensin-aldosterone system (ACE inhibitors, angiotensin II receptor blockers, and direct renin inhibitors) may cause significant hemodynamic changes on standing through multiple mechanisms. By blocking the neurohumoral axis, they determine a reduction of vasoconstrictor and sodium-retentive effects mediated by angiotensin II, with a consequent reduction of total peripheral resistance and noradrenergic peripheral transmission, decreased release of catecholamines by the adrenal medulla and modifications of hemodynamics, such as decreased renal reabsorption of sodium and water, caused by the fall in renal sympathetic tone and reduced plasma levels of aldosterone [24]. The role of ACE inhibitors in the development of orthostatic hypotension is controversial. Large population studies did not find any correlation between orthostatic hypotension and intake of ACE inhibitors even in the subgroup consisting of diabetic and hypertensive patients [9,11,47,48,52,59,60]. According to Fedorowski et al. [49], this drug class seems to be related to a decreased prevalence of orthostatic hypotension in patients with hypertension under pharmacological treatment. This may be partially explained by the protective action ACE-inhibitors exert on the kidney and by their final effect on blood pressure decrease. Considering the individual active principles, some studies show a correlation between the use of captopril and the onset of severe hypotensive events [61–63], first-dose orthostatic hypotension (estimated prevalence: 0.7-13.7% in...
general population and 2-33% in patients with heart failure [64,65] and the presence of related symptoms [66]. The short half-life and rapid action of this drug are likely to be strongly linked to these events. On the other hand, ramipril and perindopril appear to be associated with a lower prevalence of orthostatic hypotension and hypotensive events [9,61,62,67,68].

Angiotensin II receptor antagonists are not significantly connected to orthostatic hypotension, either in the elderly, or in patients with hypertension, particularly when compared to other drugs (calcium channel blockers and ACE inhibitors) [69-72].

### Diuretics

In large population studies, diuretic therapy does not appear to be related to orthostatic hypotension [9,11,51,52,73,74]. In PD patients, diuretics are related to orthostatic hypotension, as previously described [13]. The hypotensive effect may be different within diuretics subclasses. The wide majority of the studies in literature distinguish thiazide diuretics from non-thiazide diuretics. Among the latter category, only one study [49] revealed a strong association between orthostatic hypotension and potassium-sparing antialdosteronic diuretics (specifically, spironolactone) (RR 3.29, 95% CI 1.50 to 7.21).

### Table 1: Cardiovascular drugs potentially implicated in hypotensive events and orthostatic hypotension.

| PHARMACOLOGICAL CLASS | HYPOTENSION/OH (DATA SHEET) | REFERENCE | POPULATION | N | ASSOCIATION WITH OH | ADJUSTMENT FOR |
|------------------------|-----------------------------|-----------|------------|---|---------------------|----------------|
| **NITRATES**           | Hypotension/OH              |           |            |   |                     |                |
|                        | (contraindicated in presence of severe hypotension) |           |            |   |                     |                |
| Nitrates               |                             |           |            |   |                     |                |
| Vara Gonzalez 2001     |                             |           |            | 295 | RR 3.3; 95% CI 1.6-9.8 | Not specified |
| Mussi 2009             |                             |           |            | 259 | RR 5.20; 95% CI 1.99-13.61; p<0.001 | Age, sex, comorbidities, posology |
| Kamaruzzaman 2009      |                             |           |            | 3775 | RR 0.70; 95% CI 0.51-0.96; p=0.05 | Age, drugs |
| **CALCIUM CHANNELS BLOCKERS** | Hypotension |           |            |   |                     |                |
| Calcium channel blockers |                           |           |            |   |                     |                |
| Luukinen 1999          |                             |           |            | 833 | RR 2.31, 95% CI 1.14-4.68 | Not specified |
| Rose 2000              |                             |           |            | 2433 | Hypotensive: not associated with OH; Normotensive: associated with OH; p<0.0001 | Age, sex, ethnic groups |
| Rose 2006              |                             |           |            | 13152 | Hypotensive: associated with OH; p=0.05 | Not specified |
| Fedorowski 2010        |                             |           |            | 101 | RR 5.29; 95% CI 1.03-27.14; p=0.046 | Age, sex, BMI |
| **ACE-INHIBITORS**     | Hypotension/OH              |           |            |   |                     |                |
| ACE inhibitors         |                             |           |            |   |                     |                |
| Kamaruzzaman 2009      |                             |           |            | 3775 | RR 1.27; 95% CI 1.00-1.61; p=0.04 | Age; not significant if corrected for comorbidities and lifestyle |
| Fedorowski 2009        |                             |           |            | 922 | Protective effect | Not specified |
| Luukinen 1999          |                             |           |            | 833 | RR 2.29; 95% CI 1.15-4.59 | Not specified |
| Mussi 2009             |                             |           |            | 259 | RR 3.73; 95% CI 1.23-11.28; p<0.02 | Age, sex, comorbidities, posology |
| Hirai 2009             |                             |           |            | 440 | RR 1.84; 95% CI 1.01-3.38; p=0.05 | Age, sex, BMI |
| **DIURETICS**          | Hypotension/OH              |           |            |   |                     |                |
| Diuretics              |                             |           |            |   |                     |                |
| Luukinen 1999          |                             |           |            | 833 | RR 2.29; 95% CI 1.15-4.59 | Not specified |
| Mussi 2009             |                             |           |            | 259 | RR 3.73; 95% CI 1.23-11.28; p<0.02 | Age, sex, comorbidities, posology |
| Hirai 2009             |                             |           |            | 440 | RR 1.84; 95% CI 1.01-3.38; p=0.05 | Age, sex, BMI |
| **LOOP DIURETICS**     | Hypotension/OH              |           |            |   |                     |                |
| Loop diuretics         |                             |           |            |   |                     |                |
| Fedorowski 2010        |                             |           |            | 101 | RR 10.22; 95% CI 1.22-89.08; p=0.032 | Age, sex, BMI |
| **THIAZIDE DIURETICS** | Hypotension/OH              |           |            |   |                     |                |
| Thiazide diuretics     |                             |           |            |   |                     |                |
| Kamaruzzaman 2009      |                             |           |            | 3775 | RR 1.25; 95% CI 1.02-1.53; p<0.05 | Age |
| **β-BLOCKERS**         | Hypotension/OH              |           |            |   |                     |                |
| β-blockers             |                             |           |            |   |                     |                |
| Vara Gonzalez 2001     |                             |           |            | 295 | RR 4.25; 95% CI 1.15-15.48 | Not specified |
| Kamaruzzaman 2009      |                             |           |            | 3775 | RR 1.58; 95% CI 1.19-2.09; p=0.01 | Age, drugs, comorbidities, lifestyle |
| **α-BLOCKERS**         | Hypotension/OH              |           |            |   |                     |                |
| α-blockers             |                             |           |            |   |                     |                |
| Kamaruzzaman 2009      |                             |           |            | 3775 | RR 1.81; 95% CI 1.08-3.03; p<0.05 | Age |

Table 1: Cardiovascular drugs potentially implicated in hypotensive events and orthostatic hypotension. OH: orthostatic hypotension; RR: relative risk; CI 95%: 95% confidence interval; N: number of subjects.
p = 0.003), although this type of adverse drug reaction is not indicated in the data sheet of the drug. The hypotensive mechanism is mediated by the blockade of aldosterone on the final part of the distal tubule and collecting ducts, thereby reducing the reabsorption of sodium and free water.

Loop diuretics are frequently used in the treatment of heart failure. They act through inhibition of the symport Na⁺-K⁺-2Cl⁻ in the thick ascending limb of loop of Henle, leading to inhibition of reabsorption of sodium and water. The acute effect of these drugs determines an increase in the capacitance of venous district and a reduced filling pressure of the left ventricle, resulting in decreased cardiac output. Fedorowski et al. [75] detected a significant association between the intake of furosemide and orthostatic hypotension in elderly patients (RR 10.22, p=0.032), as previously shown by Poon and braun [46].

Thiazide diuretics determine the inhibition of the Na⁺-Cl symport in the distal convoluted tubule: through this mechanism, they reduce sodium and water reabsorption determining plasma volume depletion, thus possibly inducing orthostatic hypotension. Kamaruzzaman et al. [47] identified a significant correlation between this class of diuretics and orthostatic hypotension (RR 1.25, 95% CI 1.02 to 1.53). Poon and braun [46] noticed that in an elderly population 65% of patients with orthostatic hypotension was undergoing treatment with hydrochlorothiazide. Moreover, an increased prevalence of orthostatic hypotension has been detected in patients with heart failure treated with thiazide diuretics, if compared with patients treated with non thiazide diuretics [76].

β-Blockers

Drugs that act directly on the peripheral sympathetic nervous system may be classified into three categories: α-blockers, β-blockers, and drugs with mixed action.

β-blockers carry out their action, reducing the activity of renin-angiotensin-aldosterone system (blockade of β1 receptors located on the membrane of renal juxtaglomerular cells and consequent inhibition of renin release and production of angiotensin II and aldosterone) and decreasing the release of norepinephrine in response to β-adrenergic action on presynaptic receptors. They also have negative inotropic and chronotropic effects. They can be divided into three main categories, according to their prevalent action on different types of β-adrenergic receptors: non selective β-blockers, selective β1-blockers, α-β non-selective β-blockers. β-blockers do not seem to determine significant orthostatic hypotension [11,51,52,59,77,78]. In older individuals with an initial, age-related, autonomic and baroreceptorial dysfunction, the use of these drugs may affect the compensatory response to orthostasis (increase of heart rate and peripheral vasoconstriction) [79], as noticed by Kamaruzzaman et al. [47] and Vara Gonzalez et al. [54]. There are no studies comparing the prevalence of orthostatic hypotension in patients treated with different types of β-blockers.

α-Blockers

α1-antagonists inhibit the vasoconstrictor effect mediated by catecholamines through selective blockade of α1-adrenergic receptors, in the absence of changes in cardiac output, plasma renin levels, and baroreflex function. At high doses they determine further vasodilators effects, mainly on arteries, through the inhibition of the phosphodiesterase enzyme in smooth muscle cells of arterial walls. The development of orthostatic hypotension in patients treated with α1-antagonists may be fostered by the combination of plasma volume depletion and the absence of vasoconstriction mediated by α1-adrenergic receptors at standing [80]. Some studies [46,47] point out the increased risk of developing orthostatic hypotension with these drugs: it can be twice as high during intake of α1-antagonists. Prazosin is the fast-acting α1-antagonist with the greatest affinity for α1 receptor. It is, therefore, more closely related to orthostatic hypotension and syncopal events than other active ingredients, including terazosin and doxazosin. The latter are less powerful than prazosin but highly specific for α1 receptors and are thus associated with orthostatic hypotension (7-9%, mostly resulting in elderly) [81-83], while alfuzosin and tamsulosin are less associated with this adverse drug reaction (1.3-3.4%, usually asymptomatic) [84-86].

Central α2-agonists act on the α2 presynaptic receptors in the brainstem: they determine inhibition of sympathetic tone and reduction of vasopressor efferent impulses from the centers of the brainstem, determining orthostatic hypotension mediated by vasodilatation [87]. There are no studies in literature which evaluate the prevalence of orthostatic hypotension in hypertensive subjects treated with this class of drugs. However, in patients suffering from autonomic failure, the peripheral α2-agonist effect predominates, determining vasoconstriction: in these subjects, α2-agonists, such as clonidine, may increase blood pressure [88].

Phosphodiesterase-5 Inhibitors

Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) seem to be associated to exacerbation of orthostatic hypotension, especially in patients with autonomic failure (PD and multiple system atrophy) [89] and during administration of other vasoactive drugs. In particular, the concomitant administration of nitrates is contraindicated [90]. Moreover, an increased prevalence of orthostatic hypotension during treatment with sildenafil or tadalafil in combination with alpha-antagonists (for example doxazosin) has been highlighted [91]. Phosphodiesterase-5 inhibitors regulate the intracellular levels of cAMP and cGMP and, indirectly, the intracellular levels of calcium, leading to relaxation of vascular smooth muscle cells, and, therefore, arterial and venous vasodilatation.

Conclusion

Orthostatic hypotension is associated with higher morbidity and mortality. Patients with PD, diabetes, hypertension (especially if poorly controlled by therapy), and the elderly in general are often treated with multiple drugs and are at high risk for orthostatic hypotension as a consequence both of an adverse drug reaction and of the underlying autonomic dysfunction.

Antihypertensive drugs may determine orthostatic hypotension through multiple mechanisms. Although most of these drugs can theoretically lead to orthostatic hypotension according to the mechanism of action and the data sheet of the drug, in clinical practice this phenomenon does not occur constantly. This discrepancy is probably due to the establishment of compensatory mechanisms in response to the drop of blood pressure in orthostasis, to the pharmacokinetic and pharmacodynamic inter-individual variability, and to the influence of external factors or comorbidities which act on autonomic nervous system and renal function. Drug classes at greater risk for development or exacerbation of orthostatic hypotension may be identified in nitrates, α-antagonists and non-dihydropyridine calcium channel blockers, while ACE-inhibitors, angiotensin II receptor antagonists, dihydropyridine calcium channel blockers and β-blockers carry a lower risk of orthostatic hypotension. In the treatment of hypertension of patients at risk of orthostatic hypotension, such as the...
elderly, and subjects with diabetes and PD, it is advisable to use the latter drugs, associated to a lower risk of orthostatic hypotension.

There are no experimental data regarding the prevalence of orthostatic hypotension in elderly patients treated with centrally-acting antihypertensive drugs, so the role of these drugs in the development of orthostatic hypotension is controversial.

In the treatment of benign prostatic hypertrophy in subjects who also suffer from hypertension, a lower prevalence of hypotensive events during protracted treatment with alfuzosin and tamsulosin if compared to other -antagonists has been highlighted. Again, in the treatment of benign prostatic hypertrophy of patients at risk of orthostatic hypotension, such as the elderly, and subjects with diabetes and PD, it is advisable to use alfuzosin or tamsulosin, associated to a lower risk of orthostatic hypotension.

Furthermore, the optimization of a pharmacological treatment of hypertension seems to be related to a reduced prevalence of orthostatic hypotension.

Pertaining to drugs commonly used in neurological and psychiatric disorders, it is appropriate to evaluate blood pressure in clinostatism to their adverse effects, both cardiovascular and neuro-psychiatric.

Simultaneous presence of two or more drugs in combination therapy often leads to a synergistic or additive effect, which contributes to a more significant reduction of blood pressure levels when compared to the action of a single drug. Considering the correlation between the number of vasoactive drugs and the blood pressure drop in orthostatism, after the detection of drug-induced orthostatic hypotension, a reduction in the number and type of hypotensive drugs is advisable, in order to reduce morbidity, mortality and symptoms related to orthostatic hypotension, as well as a selection of therapies associated to a lower risk of orthostatic hypotension.

References

1. Freeman R, Wieling W, Axelrod FB, Benditt DG, Benaroch E, et al. (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21: 69-72.
2. Spallone V, Morgard R, Fedele T, D’Amato C, Maiello MR (2009) Reappraisal of the diagnostic role of orthostatic hypotension in diabetes. Clin Auton Res 19: 58-64.
3. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, et al. (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71: 670-676.
4. Mathias CJ (1995) Orthostatic hypotension: causes, mechanisms, and influencing factors. Neurology 45: S6-S11.
5. Musci C, Ungar A, Salvio G, Menozzi C, Bartoletti A, et al. (2009) Orthostatic hypotension as cause of syncope in patients older than 65 years admitted to emergency departments for transient loss of consciousness. J Gerontol A Biol Sci Med Sci 64: 801-806.
6. Shibao C, Grijelva CG, Raj SR, Biaggioni I, Griffin MR (2007) Orthostatic hypotension-related hospitalizations in the United States. Am J Med 120: 975-980.
7. Olde Nordkamp LR, van Dijk N, Ganzeboom KS, Reitsma JB, Luitse JS, et al. (2009) Syncope prevalence in the ED compared to general practice and population: a strong selection process. Am J Emerg Med 27: 271-279.
8. Fedorowski A, Slavenov L, Hedblad B, Berglund G, Nilsson PM, et al. (2010) Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur Heart J 31: 85-91.
9. Rose KM, Tyroler HA, Nardo CJ, Arnett DK, Light KC, et al. (2000) Orthostatic hypotension and the incidence of coronary heart disease: The Atherosclerosis Risk in Communities study. Am J Hypertens 13: 571-578.
10. Eigenbrodt ML, Rose KM, Couper DJ, Arnett DK, Smith R, et al. (2000) Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study. Stroke 31: 2307-2313.
11. Rose KM, Eigenbrodt ML, Biga RL, Couper DJ, Light KC, et al. (2006) Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. Circulation 114: 630-636.
12. Ziemssen T, Reichmann H (2010) Cardiovascular autonomic dysfunction in Parkinson’s disease. J Neurol Sci 289: 74-80.
13. Ha AD, Bonow CH, York MK, Jankovic J (2011) The prevalence of symptomatic orthostatic hypotension in patients with Parkinson’s disease and atypical parkinsonism. Parkinsonism Relat Disord 17: 625-628.
14. Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, et al. (2012) Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord.
15. Bouhaddi M, Vuiller F, Fortrat JO, Cappelle S, Henriet MT, et al. (2004) Implied cardiovascular autonomic control in newly and long-term-treated patients with Parkinson’s disease: involvement of L-dopa therapy. Auton Neurosci 116: 30-38.
16. Haapaniemi TH, Kallio MA, Korpelainen JT, Suominen K, Tolonen U, et al. (2000) Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson’s disease. J Neurol 247: 868-874.
17. Wood LD (2010) Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson’s disease. Drugs Aging 27: 295-310.
18. Bhattacharya KF, Nouri S, Olanow CW, Yahr MD, Kaufmann H (2003) Selegeline in the treatment of Parkinson’s disease: its impact on orthostatic hypotension. Parkinsonism Relat Disord 9: 221-224.
19. Stryjer R, Klein C, Treves TA, Rabey JM (2005) The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson’s disease patients. Acta Neurol Scand 111: 89-94.
20. Churchyard A, Mathias CJ, Boonkonchuen P, Lees AJ (1999) Autonomic effects of selegeline: possible cardiovascular toxicity in Parkinson’s disease. J Neurol Neurosurg Psychiatry 63: 228-234.
21. Churchyard A, Mathias CJ, Lees AJ (1999) Selegiline-induced postural hypotension in Parkinson’s disease: a longitudinal study on the effects of drug withdrawal. Mov Disord 14: 246-251.
22. Gerlach M, Youdim MB, Riederer P (1996) Pharmacology of selegiline. Neurology 47: S13-S145.
23. Ooi WL, Barrett S, Hossain M, Kelley-Gagnon M, Lipsitz LA (1997) Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population. JAMA 277: 1299-1304.
24. Brunton A, Chabner BA, Chabner B, Knollman B (2011) Goodman and Gilman’s The Pharmacological Basis of Therapeutics. (12thedn), Mc Graw Hill Medical, New York.
25. Shi SJ, Garcia KM, Meck JV (2003) Ternazepam, but not zolpidem, causes cardiovascular hypotension in astronauts after spaceflight. J Cardiovasc Pharmacol 41: 31-39.
26. Strogatz DS, Keenan NL, Barnett EM, Wagner EH (1991) Correlates of postural hypotension in a community sample of elderly blacks and whites. J Am Geriatr Soc 39: 562-566.
27. Yang JJ, Li WY, Jil Q, Wang ZY, Sun J, et al. (2005) Local anesthesia for functional endoscopic sinus surgery employing small volumes of epinephrine-containing solutions of lidocaine produces profound hypotension. Acta Anaesthesiol Scand 49: 1471-1476.
28. Enlund M, Mentell O, Krokmanov L (2001) Unintentional hypotension from lidocaine infiltration during orthognathic surgery and general anaesthesia. Acta Anaesthesiol Scand 45: 294-297.
Citation: Milazzo V, Stefano CD, Servo S, Crudo V, Fulcheri C, et al. (2012) Drugs and Orthostatic Hypotension: Evidence from Literature. J Hypertens 1:104. doi:10.4172/2167-1095.1000104

Page 7 of 8

29. Fassi J, High KM, Stephenson ER, Yarotskyy E, Elmslie KS (2011) The intravenous anesthetic propofol inhibits human L-type calcium channels by enhancing voltage-dependent inactivation. J Clin Pharmacol 51: 719-730.

30. Bijker JB, van Klei WA, Kappen TH, van Wolswinkel L, Moones KG, et al. (2007) Incidence of intraoperative hypotension as a function of the chosen definition: literature definitions applied to a retrospective cohort using automated data collection. Anesthesiology 107: 213-220.

31. Franck M, Radtke FM, Prsah C, Seeling M, Papakilla N, et al. (2011) Documented intraoperative hypotension according to the three most common definitions does not match the application of antihypertensive medication. J Int Med Res 39: 846-856.

32. Hemmingsen C, Nielsen JE (1991) Intravascular ketamine for prevention of severe hypotension during spinal anaesthesia. Acta Anaesthesiol Scand 35: 755-757.

33. Thomas MC, Jennett-Reznick AM, Patanwala AE (2011) Combination of ketamine and propofol versus either agent alone for procedural sedation in the emergency department. Am J Health Syst Pharm 68: 2248-2256.

34. Ozkokac I, Altukanya H, Ozer Y, Ayyoglu H, Demirel CB, et al. (2005) Comparison of ephedrine and ketamine in prevention of injection pain and hypotension due to propofol induction. Eur J Anaesthesiol 22: 44-48.

35. Craig GM (1994) Clinical presentation of orthostatic hypotension in the elderly. Postgrad Med J 70: 638-642.

36. Pacher P, Kecskemeti V (2004) Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?. Curr Pharm Des 10: 2463-2475.

37. Alli C, Avanzini F, Betteli G, Colombo F, Corso R, et al. (1992) Prevalence and variability of orthostatic hypotension in the elderly. Results of the ‘Italian study on blood pressure in the elderly’ (SPAA). The ‘Gruppo di Studio Sulla Pressione Arteriosa nell’Anziano’. Eur Heart J 13: 178-182.

38. Darowski A, Chambers SA, Chambers DJ (2009) Antidepressants and falls in the elderly. Drugs Aging 26: 381-394.

39. Jefferson JW (1975) A review of the cardiovascular effects and toxicity of tricyclic antidepressants. Psychosom Med 37: 160-179.

40. Ungvari Z, Pacher P, Kecskemeti V, Koller A (1999) Fluoxetine dilates isolated small cerebral arteries of rats and attenuates constrictions to serotonin, norepinephrine, and a voltage-dependent Ca(2+) channel opener. Stroke 30: 1949-1954.

41. Cherin P, Colvez A, Deville de Periere G, Sereni D (1997) Risk of syncope in the elderly and consumption of drugs: a case-control study. J Clin Epidemiol 50: 313-320.

42. Meitzler HY (1998) Adverse effects of the atypical antipsychotics: Collaborative Working Group on Clinical Trial Evaluations. J Clin Psychiatr 59: 17-22.

43. Shi SJ, Piatts ZH, Ziegler MG, Meck JV (2011) Effects of promethazine and midodrine on orthostatic tolerance. Aviat Space Environ Med 82: 9-12.

44. Fedorowski A, Hedblad B, Engstrom G, Gustav Smith J, Melander O (2010) Orthostatic hypotension and long-term incidence of atrial fibrillation: the Malmo Preventive Project. J Intern Med 268: 383-389.

45. Franceschini N, Rose KM, Astor BC, Couper D, Vuppunturu S (2010) Orthostatic hypotension and incident chronic kidney disease: the atherosclerosis risk in communities study. Hypertension 56: 1054-1059.

46. Poon IO, Braun U (2005) High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharmacol Ther 30: 173-178.

47. Kamaruzzaman S, Watt H, Carson C, Ebrahim S (2010) The association of potentially causative medications among elderly veterans. J Intern Med 159: 1350-1356.

48. Luukinen H, Kosti K, Lapialla P, Kivela SL (1999) Prognosis of diastolic and systolic orthostatic hypotension in older persons. Arch Intern Med 159: 273-280.

49. Varia Gonzalez LA, Munoz Cacho P (2000) Orthostatic hypotension and arterial hypertension. Are all calcium antagonists equal? Med Clin (Barc) 115: 516.

50. Julius S (1988) Amlodipine in hypertension: an overview of the clinical dossier. J Cardiovasc Pharmacol 7: 527-533.

51. Leonetti G (1989) The clinical performance of nicardpine in elderly hypertensive patients with concomitant diseases. Am Heart J 117: 266-269.

52. Forette F, McClaran J, Herry MP, Bouchacourt P, Henry JF (1989) Nicardpine in elderly patients with hypertension: a review of experience in France. Am Heart J 117: 256-261.

53. Fedorowski A, Burri P, Juul-Moller S, Melander O (2010) A dedicated investigation unit improves management of syncopal attacks (Syncope Study of Unselected Population in Malmo–SYSTEMA I). Europace 12: 1322-1328.

54. Hirai FE, Moss SE, Klein BE, Klein R (2009) Postural blood pressure changes and associated factors in long-term Type 1 diabetes: Wisconsin Epidemiologic Study of Diabetic Retinopathy. J Diabetes Complications 23: 83-88.

55. Van Buren PN, Adams-Huet B, Toto RD (2010) Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. J Invest Med 58: 950-956.

56. Anthopoulos L, Apostolou T, Bonoris F, Fousas S, Lefkos N, et al. (2001) Comparative haemodynamic responses to the first dose of short- and long-acting ACE inhibitors in patients with congestive heart failure. Curr Med Res Opin 17: 290-297.

57. Hiait R, Piot O, Gallois H, Hanania G (1999) Blood pressure response to the first 36 hours of haemodynamic therapy with perindopril versus captopril. French General Hospitals National College of Cardiologists. J Cardiovasc Pharmacol 33: 953-959.

58. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group (1995) ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrile, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345: 669-685.

59. Cody RJ, Covit AB, Schaer GL, Laragh JH (1983) Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure. J Am Coll Cardiol 1: 1154-1159.

60. Gayet JL (2002) The OPTIMAAL trial: losartan or captopril after acute myocardial infarction. Lancet 360: 1884-1885.

61. Mehagnoul-Schipper DJ, Collier WN, Hoefnagels WHL, Verheugt FWA, Jansen RWMM (2002) Effects of furosemide versus captopril on postprandial and orthostatic blood pressure and on cerebral oxygenation in patients > or = 70 years of age with heart failure. Am J Cardio 90: 596-600.

62. Yajnik VH, Vatsraj DJ, Acharya HK, Yajnik NV, Vyas NR, et al. (1994) Ramipril vs captopril in mild to moderate hypertension. J Assoc Physicians India 42: 120-123.

63. Vitovec J, Spinar J (2000) First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Slovak Investigator Group. Eur J Heart Fail 2: 120-123.

64. Spinar J, Vitovec J, Pluhacek L, Fischerova B, et al. (2000) First-dose hypotension after angiotensin-converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure. J Am Coll Cardiol 1: 1154-1159.

65. Alderman JW, Oparil S, Dyke S, Harris F, Kief J, James D, et al. (1995) Prevalence, predisposing factors, and prognostic importance of postural hypotension. Arch Intern Med 155: 930-935.

66. Wu JS, Lu FH, Yang YC, Chang CJ (1999) Postural hypotension and postural dizziness in patients with non-insulin-dependent diabetes. Arch Intern Med 159: 1350-1356.

67. Vattikuti NB, Kosti K, Lapialla P, Kivela SL (1999) Prognosis of diastolic and systolic orthostatic hypotension in older persons. Arch Intern Med 159: 273-280.

68. Varia Gonzalez LA, Munoz Cacho P (2000) Orthostatic hypotension and arterial hypertension. Are all calcium antagonists equal? Med Clin (Barc) 115: 516.

69. Julius S (1988) Amlodipine in hypertension: an overview of the clinical dossier. J Cardiovasc Pharmacol 7: 527-533.
72. Weir MR, Neutel JM, Bhaumik A, De Obaldia ME, Lapuerta P (2007) The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk. J Clin Hypertens (Greenwich) 9: 23-30.
73. Myers MG, Kearns PM, Kennedy DS, Fisher RH (1978) Postural hypotension and diuretic therapy in the elderly. Can Med Assoc J 119: 581-585.
74. Wu JS, Yang YC, Lu FH, Wu CH, Wang RH, et al. (2009) Population-based study on the prevalence and risk factors of orthostatic hypotension in subjects with pre-diabetes and diabetes. Diabetes Care 32: 69-74.
75. Fedorowski A, Engstrom G, Hedblad B, Melander O (2010) Orthostatic hypotension predicts incidence of heart failure: the Malmo preventive project. Am J Hypertens 23: 1209-1215.
76. Heseltine D, Bramble MG (1988) Loop diuretics cause less postural hypotension than thiazide diuretics in the frail elderly. Curr Med Res Opin 11: 232-235.
77. Brogden RN, Speight TM, Avery GS (1975) Timolol: a preliminary report of its pharmacological properties and therapeutic efficacy in angina and hypertension. Drugs 9: 164-177.
78. Luukinen H, Koski K, Laippala P, Airaksinen KE (2004) Orthostatic hypotension and the risk of myocardial infarction in the home-dwelling elderly. J Intern Med 255: 486-493.
79. Cleophas TJ, Grabowski I, Niemeyer MG, Makel WM, van der Wall EE (2002) Paradoxical pressor effects of beta-blockers in standing elderly patients with mild hypertension: a beneficial side effect. Circulation 105: 1669-1671.
80. Sica DA (2005) Alpha1-adrenergic blockers: current usage considerations. J Clin Hypertens (Greenwich) 7: 757-762.
81. Dull P, Reagan RW Jr, Bahnsen RR (2002) Managing benign prostatic hyperplasia. Am Fam Physician 66: 77-84.
82. Lepor H, Jones K, Williford W (2000) The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. J Urol 163: 1134-1137.
83. Chapple CR (2005) A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms. Rev Urol 4: 322-330.
84. Narayan P, Evans CP, Moon T (2003) Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 170: 498-502.
85. Roehrborn CG (2001) Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 58: 983-995.
86. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P (2000) Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol 37: 306-313.
87. Engelmann K (1988) Side effects of sympatholytic antihypertensive drugs. Hypertension 11: 30-33.
88. Robertson D, Goldberg MR, Hollister AS, Wade D, Robertson RM (1983) Clonidine raises blood pressure in severe idiopathic orthostatic hypotension. Am J Med 74: 193-200.
89. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ (2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in Parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71: 371-374.
90. Prisant LM (2006) Phosphodiesterase-5 inhibitors and their hemodynamic effects. Curr Hypertens Rep 8: 345-351.
91. Kloner RA (2004) Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 110: 3149-3155.
92. Spallone V, Bellavere F, Scironti L, Maule S, Quadri R, et al. (2011) Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovasc Dis 21: 69-78.